- Home
- UEIC vs MAIA Comparison
UEIC vs MAIA Comparison
Compare UEIC & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UEIC | MAIA |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | 3838 | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.3M | 49.3M |
| IPO Year | 1993 | 2022 |
Fundamental Metrics
Financial Performance| Metric | UEIC | MAIA |
|---|---|---|
| Price | $3.59 | $1.54 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.25 | N/A |
| AVG Volume (30 Days) | 81.8K | ★ 903.3K |
| Earning Date | 02-19-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $390,997,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.35 | N/A |
| 52 Week Low | $2.69 | $0.87 |
| 52 Week High | $11.27 | $2.74 |
Technical Indicators
Market Signals| Indicator | UEIC | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 64.13 | 59.05 |
| Support Level | $3.07 | $1.33 |
| Resistance Level | $3.15 | $1.64 |
| Average True Range (ATR) | 0.14 | 0.17 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 98.36 | 64.77 |
Price Performance
Historical ComparisonAbout UEIC Universal Electronics Inc.
Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.